Comparing Contineum Therapeutics (NASDAQ:CTNM) & Adherex Technologies (NASDAQ:FENC)

Contineum Therapeutics (NASDAQ:CTNM) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Contineum Therapeutics and Adherex Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1	1	4	0	2.50
Adherex Technologies	1	1	4	0	2.50

Contineum Therapeutics presently has a consensus price target of $22.17, indicating a potential upside of 65.67%. Adherex Technologies has a consensus price target of $17.00, indicating a potential upside of 58.73%. Given Contineum Therapeutics’ higher possible upside, equities analysts clearly believe Contineum Therapeutics is more favorable than Adherex Technologies.

Institutional & Insider Ownership

55.5% of Adherex Technologies shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Contineum Therapeutics and Adherex Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Adherex Technologies	-6.09%	-5.71%	-2.37%

Risk & Volatility

Contineum Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Earnings & Valuation

This table compares Contineum Therapeutics and Adherex Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50.00 million	10.07	-$59.98 million	($1.73)	-7.73
Adherex Technologies	$44.64 million	8.43	-$9.74 million	($0.13)	-82.38

Adherex Technologies has lower revenue, but higher earnings than Contineum Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Adherex Technologies beats Contineum Therapeutics on 7 of the 12 factors compared between the two stocks.

About Contineum Therapeutics

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

About Adherex Technologies

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.